FA
VRTX icon

Fiduciary Alliance’s Vertex Pharmaceuticals VRTX Stock Holding History

Fiduciary Alliance’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5,583
Closed -$2.47M – 585
2026
Q1 		$2.47M Buy
5,583
+755
+16% +$352K 0.15% 159
2025
Q4 		$2.19M Buy
+4,828
New +$2.08M 0.14% 157

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

Fiduciary Alliance's VRTX Position: Q2 2026 in Review

Fiduciary Alliance sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 5,583 shares — an estimated $2.47M sold.

Fiduciary Alliance first reported a position in VRTX in Q4 2025 and held it in 2 quarters. The position peaked at $2.47M in Q1 2026. 324 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Fiduciary Alliance reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Fiduciary Alliance sold 5,583 Vertex Pharmaceuticals shares in Q2 2026, an estimated $2.47M.
  • Fiduciary Alliance first reported a position in Vertex Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Fiduciary Alliance's Vertex Pharmaceuticals position peaked at $2.47M in Q1 2026.
  • 324 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Fiduciary Alliance's 13F filing for Q2 2026, filed 20 Jul 2026.